Questions
DSIP and Selank questions
The questions that return after the interesting experiment: does it help people, how certain is that, and what is still unknown about safety?
Does DSIP help people sleep?
An early pilot in six middle-aged chronic insomniacs reported longer sleep, fewer interruptions, slightly more REM and no daytime sedation after intravenous DSIP. The 2006 review judged the sleep evidence weakly documented. I can acknowledge the positive pilot without claiming a dependable treatment effect. The broader DSIP record remains inconsistent.
Is Selank studied for sleep or anxiety?
Its molecular research centers on anxiety-related mechanisms, including GABA receptor modulation and inhibition of enkephalin breakdown. The rat chronic-stress study examined anxiety-related behavior. A sleep benefit is sometimes described in anecdotal community reports, which provide no clinical evidence that Selank treats insomnia.
Community experiences
DSIP accounts range from easier sleep and vivid dreams to no effect, delayed drowsiness or a groggy morning. Selank accounts often describe quieter anxiety with preserved clarity, alongside non-response, tiredness and nasal irritation. These are anecdotal accounts, not clinical evidence. I trust a collection of enthusiastic accounts less when the quiet failures have been left out.
DSIP and Selank approval
Neither DSIP nor Selank has FDA or EMA approval. Selank is registered as a prescription anxiolytic in Russia. U.S. prescription access requires a separate clinical assessment, and compounded prescription forms have no FDA approval. Research-labelled material has separate quality uncertainties and is not intended for human consumption. A prescription decision and regulatory approval answer different questions.
Can the two be combined safely?
There are no established human safety data for a DSIP–Selank combination. DSIP's mechanism remains unresolved; Selank's pharmacology spans several signaling systems, and its immune effects in patients add further questions. Similar interests in stress or sleep do not establish compatibility. This site supplies no combined-use plan.
What about long-term effects and sport?
Long-term human safety remains inadequately characterized for both compounds. Pregnancy, breastfeeding and significant pre-existing conditions lack an established safety basis. Interactions with sedatives, opioids and other medicines remain important uncertainties in the DSIP and Selank literature. Persistent sleep difficulty or impairing anxiety also calls for assessment of its cause.
WADA's S0 catch-all for non-approved substances may apply to either compound. Their absence from a specific named listing cannot establish permission in competitive sport. This page offers no personal eligibility decision under anti-doping rules.